News | Radiation Therapy | January 03, 2017

NCCN Guidelines Recommend Y-90 Microspheres for Metastatic Colorectal Cancer Treatment

Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases

metastatic colorectal cancer, mCRC, Sirtex, NCCN guidelines, Y-90 microspheres

January 3, 2017 — Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.

The new NCCN Guidelines are available online at https://www.nccn.org/professionals/physician_gls/f_guidelines.asp

According to Sirtex Americas CEO Kevin Richardson, the company has positive signals in the first-line setting from the results to-date of the SIRFLOX study1 and expects results from the SIRFLOX, FOXFIRE and FOXFIRE Global studies in the first half of 2017.

These findings are also supported by the landmark MORE study2, a large retrospective analysis conducted in the United States with SIR-Spheres Y-90 resin microspheres in more than 600 mCRC patients. The MORE study helped to increase the understanding of SIRT as a treatment option for patients who have failed multiple lines of chemotherapy, while highlighting the positive aspects of the safety and efficacy of the protocol for patients of all ages.

“Clinical research has shown that SIRT brings patients with colorectal liver metastases improved and prolonged quality of life,” said lead investigator of the MORE study, Andrew S. Kennedy, M.D., FACRO, director, radiation oncology research at Sarah Cannon Research Institute, Nashville, Tenn. “We look forward to expanding access to this outpatient procedure, which has demonstrated minimal side effects, to improve outcomes for this population of patients and advance the standard of care.”

SIR-Spheres Y-90 resin microspheres are the first and only microspheres with U.S. Food and Drug Administration (FDA) premarket approval (PMA) for colorectal cancer that has metastasized to the liver.3

For more information, visit www.sirtex.com.

References

1. van Hazel GA, Heinemann V, Sharma NK et al. SIRFLOX: Randomized Phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 2016; 34: 1723–1731.

2. Kennedy AS, Ball D, Cohen SJ et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for 90Y resin microspheres. Journal of Gastrointestinal Oncology. 2015; 6: 134–142

3. SIR-Spheres microspheres (Yttrium-90 Microspheres) Product Information. Available at: www.sirtex.com/us/clinicians/package-insert/. Assessed on December 8, 2016.

 

Related Content

"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...